110PImmune prognostic index (IPI) and hyper-progressive...

Annals of Oncology 2018 / 10 Vol. 29; Iss. suppl_8

110PImmune prognostic index (IPI) and hyper-progressive disease (HPD) in patients (pts) exposed to targeted agents (TAs) in phase I trials (Ph1T): Can lessons from immune checkpoint inhibitors (ICIs) be translated to other scenarios?

Matos Garcia, I, Azaro, A, Viaplana, C, Hierro, C, Martin-Liberal, J, Brana, I, Gardeazabal, I, Gomila, P, Vieito Villar, M, Ochoa De Olza Amat, M, Elez Fernandez, E, Oliveira, M, Oaknin, A, Verdaguer
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
29
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdy269.108
Date:
October, 2018
File:
PDF, 78 KB
2018
Conversion to is in progress
Conversion to is failed